BDR Pharma signs agreement with DRDO to produce COVID-19 drug 2-DG

Date: 2021-07-27   Author: Pankaj Singh  Category: #news

BDR Pharma signs agreement with DRDO to produce COVID-19 drug 2-DG

BDR Pharma has reportedly signed a licensing agreement with the DRDO (Defence Research and Development Organisation) to produce, distribute, and promote COVID-19 drug 2-DG (2-Deoxy-D-Glucose) in India.

The Mumbai-based company has inked an agreement with DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) and the Defence Research and Development Establishment (DRDE) for producing, distributing, and promoting the COVID-19 drug in the country.

Last month, the DCGI (Drugs Controller General of India) sanctioned the oral medication as an immunity booster for emergency usage in COVID-19 patients with mild to severe symptoms.

Recently, DRDO signed agreements with four key generic medicine producers from India for developing 2-DG drugs. The DRDE has manufactured the 2-DG and its clinical trials were performed by the DRDO lab INMAS in partnership with Dr. Reddy's Laboratories.

BDR Pharma has already applied for restricted emergency use authorization to the Drug Controller General of India (DCGI), in order to use the drug for treating COVID-19 patients in India.

Dharmesh Shah, the CMD of BDR Pharmaceuticals, supposedly commented that the company is delighted to sign a license pact with the DRDO and add 2-DG to its COVID-19 product portfolio. The goal of this arrangement is to make this drug available to as many eligible Indian COVID-19 patients as possible.

He added that the company is aiming at increasing the availability of successful treatment and will coordinate manufacturing accordingly. This will ensure there is no dearth of drugs for people fighting this devastating disease.

Shah further said that this partnership will cater to more unmet medical needs, by increasing the scope of identification and development of therapy options for COVID-19.

2-DG will be offered in a sachet in powdered form and can be consumed orally by dissolving it in water, and will be made available at an economical price point.

Source credits:

https://www.moneycontrol.com/news/india/bdr-pharma-inks-license-agreement-with-drdo-to-produce-covid-19-drug-2-dg-7224931.html



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Isopropyl Acetoacetate (Cas 542-08-5) Professional Market Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand and Forecast till 2029

Author: Ashwin Naphade

The New Research Report on Global Isopropyl Acetoacetate (Cas 542-08-5) Professional Market till 2029 added by Market Study Report  studies the current and upcoming Market Size, Share, Demand, Growth Trend and Forecast.

The Isopropy...


Industrial Wastewater Treatment Plants Professional Market Business Analysis 2022 by CAGR, Share, Revenue and Prominent Key Players to 2029

Author: Ashwin Naphade

Report studies Global Industrial Wastewater Treatment Plants Professional market and focuses on the top Manufacturers, Market Segment by Countries, Split by Product Types (with sales, revenue, price, market share of each type), Split by applicatio...


Anti-Static Fibres Professional Market Recent Developments & Emerging Trends To 2029

Author: Ashwin Naphade

This is a professional and in-depth study on the current state of the Anti-Static Fibres Professional Market. Report initially provides a basic overview of the industry that covers definition, applications and manufacturing technology, post which ...